126 related articles for article (PubMed ID: 28503792)
1. Synthetic cannabinoid use in an acute psychiatric inpatient unit.
Clancy RV; Hodgson RC; Kendurkar A; Terry MA; Dadd L; Clancy DM; Ryan K; Hatzistylis M; Tinman BG
Int J Ment Health Nurs; 2018 Apr; 27(2):600-607. PubMed ID: 28503792
[TBL] [Abstract][Full Text] [Related]
2. Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.
Bonar EE; Ashrafioun L; Ilgen MA
Drug Alcohol Depend; 2014 Oct; 143():268-71. PubMed ID: 25096272
[TBL] [Abstract][Full Text] [Related]
3. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
Macfarlane V; Christie G
Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
[TBL] [Abstract][Full Text] [Related]
4. The Synthetic Cannabinoids Phenomenon.
Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
[TBL] [Abstract][Full Text] [Related]
5. [Which psychiatric comorbidities in cannabis dependence during adolescence? Comparison of outpatients and controls].
Dorard G; Bungener C; Phan O; Edel Y; Corcos M; Berthoz S
Encephale; 2018 Feb; 44(1):2-8. PubMed ID: 27637871
[TBL] [Abstract][Full Text] [Related]
6. Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study.
Aharonovich E; Liu X; Samet S; Nunes E; Waxman R; Hasin D
Am J Psychiatry; 2005 Aug; 162(8):1507-14. PubMed ID: 16055773
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
[TBL] [Abstract][Full Text] [Related]
8. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
[TBL] [Abstract][Full Text] [Related]
10. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
[TBL] [Abstract][Full Text] [Related]
11. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia.
Lai HM; Sitharthan T
Am J Drug Alcohol Abuse; 2012 Nov; 38(6):567-74. PubMed ID: 22746224
[TBL] [Abstract][Full Text] [Related]
12. Cannabis and Alcohol Abuse Among First Psychotic Episode Inpatients.
Katz G; Kunyvsky Y; Hornik-Lurie T; Raskin S; Abramowitz MZ
Isr J Psychiatry Relat Sci; 2016; 53(3):10-15. PubMed ID: 28492376
[TBL] [Abstract][Full Text] [Related]
13. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
14. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample.
Sara GE; Burgess PM; Malhi GS; Whiteford HA; Hall WC
Aust N Z J Psychiatry; 2014 Nov; 48(11):1036-47. PubMed ID: 24819935
[TBL] [Abstract][Full Text] [Related]
15. Synthetic cannabinoid use: a case series of adolescents.
Castellanos D; Singh S; Thornton G; Avila M; Moreno A
J Adolesc Health; 2011 Oct; 49(4):347-9. PubMed ID: 21939863
[TBL] [Abstract][Full Text] [Related]
16. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
[TBL] [Abstract][Full Text] [Related]
17. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
[TBL] [Abstract][Full Text] [Related]
18. Synthetic cannabinoid use: recognition and management.
Castellanos D; Thornton G
J Psychiatr Pract; 2012 Mar; 18(2):86-93. PubMed ID: 22418399
[TBL] [Abstract][Full Text] [Related]
19. Synthetic cannabinoid use disorder: an update for general psychiatrists.
Grigg J; Manning V; Arunogiri S; Lubman DI
Australas Psychiatry; 2019 Jun; 27(3):279-283. PubMed ID: 30663326
[TBL] [Abstract][Full Text] [Related]
20. Cannabis use in a large sample of acute psychiatric admissions.
Mathers DC; Ghodse AH; Caan AW; Scott SA
Br J Addict; 1991 Jun; 86(6):779-84. PubMed ID: 1878628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
